Your browser doesn't support javascript.
loading
Prioritizing US Cervical Cancer Prevention With Results From a Geospatial Model.
Kish, Jonathan K; Rolin, Alicia I; Zou, Zhaohui; Cucinelli, James E; Tatalovich, Zaria; Saraiya, Mona; Altekruse, Sean F.
Afiliação
  • Kish JK; National Cancer Institute, Rockville.
  • Rolin AI; National Cancer Institute, Rockville.
  • Zou Z; Information Management Services, Silver Spring, MD.
  • Cucinelli JE; Information Management Services, Silver Spring, MD.
  • Tatalovich Z; National Cancer Institute, Rockville.
  • Saraiya M; Centers for Disease Control and Prevention, Atlanta, GA.
  • Altekruse SF; National Cancer Institute, Rockville.
J Glob Oncol ; 2(5): 275-283, 2016 Oct.
Article em En | MEDLINE | ID: mdl-28413829
PURPOSE: To determine if differences in screening and vaccination patterns across the population may accentuate ethnic and geographic variation in future burden of disease. METHODS: Using Cancer in North America data provided by the North American Association of Central Cancer Registries, county cervical cancer incidence trends from 1995 to 2009 were modeled for the entire United States using ecologic covariates. Rates for health service areas were also modeled by ethnicity. State-level incidence was mapped together with Papanicolaou (Pap) screening, past 3 years (women ≥ 18 years old), and three-dose human papillomavirus (HPV) vaccine coverage (girls 13 to 17 years old) to identify potential priority areas for preventive services. RESULTS: US cervical cancer incidence decreased more during the periods 1995 to 1999 and 2000 to 2004 than during the period 2005 to 2009. During these 15 years, the most affected areas became increasingly confined to Appalachia, the lower Mississippi Valley, the Deep South, Texas, and Florida. Hispanic and black women experienced a higher incidence of cervical cancer than both white and Asian and Pacific Islander women during each period. Women in 10 of 17 states/districts with a high incidence (≥ 8.14/100,000) reported low Pap testing (< 78.5%), HPV vaccine coverage (< 33.9%), or both prevention technologies. CONCLUSION: The decline in cervical cancer incidence has slowed in recent years. Access to HPV vaccination, targeted screening, and treatment in affected populations is needed to reduce cervical cancer disparities in the future.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2016 Tipo de documento: Article